ABSTRACT
OBJECTIVE@#To investigate the relationship between serum matrix metalloproteinase-1(MMP-1) and matrix metalloproteinase-2(MMP-2) and the formation of deep venous thrombosis(LDVT) in lower extremity patients after surgery for lower extremity fracture, and to analyze the value of MMP-1 and MMP-2 in predicting the occurrence of LDVT after lower extremity fracture.@*METHODS@#From June 2018 to December 2021, 352 patients who planned to receive surgical treatment of lower limb fracture in our hospital were selected as the research objects. Venous blood was collected at 1, 2 and 3 days after surgery, respectively, and serum MMP-1 and MMP-2 levels were detected. The incidence of LDVT during hospitalization was analyzed, and the risk factors of postoperative LDVT in patients with lower limb fracture surgery and the predictive value of MMP-1 and MMP-2 for LDVT were analyzed.@*RESULTS@#LDVT occurred in 40 patients (LDVT group), the incidence of LDVT was 11.36%, and 312 patients did not occurred(no occurred group). The serum levels of MMP-1 and MMP-2 in LDVT group increased gradually after surgery; the serum levels of MMP-1 and MMP-2 in the no occurred group increased slightly after surgery at 2 days and then decreased at 3 days after surgery (P<0.01);the serum levels of MMP-1 and MMP-2 in LDVT group were higher than those in the no occurred group at 2 days and 3 days after surgery (P<0.05). Serum levels of MMP-1 and MMP-2 were positively correlated with serum levels of interleukin-6 (IL-6), IL-8 and tumor necrosis factor -α (TNF-α) in LDVT patients at 2 days and 3 days postoperatively (P<0.05). Operative time, MMP-1 and MMP-2 postoperative 3 days were related to the occurrence of LDVT after lower limb fracture (P<0.01). The area under the curve(AUC) predicted by MMP-1 and MMP-2 postoperative 3 days for LDVT after lower limb fracture was 0.738 and 0.744 respectively, and the AUC predicted by combined MMP-1 and MMP-2 was 0.910, which was higher than that predicted by single indicator(Z=2.819 and 2.025, P<0.05).@*CONCLUSION@#High levels of MMP-1 and MMP-2 after lower extremity fracture are closely related to the occurrence of LDVT, and 3 d mMP-1 and MMP-2 after surgery maybe used as evaluation indexes for LDVT risk prediction.
Subject(s)
Humans , Lower Extremity/surgery , Matrix Metalloproteinase 1/blood , Matrix Metalloproteinase 2/blood , Risk Factors , Venous Thrombosis/etiology , Fractures, Bone/surgeryABSTRACT
The aim of the present study was to identify specific markers that mirror liver fibrosis progression as an alternative to biopsy when biopsy is contraindicated, especially in children. After liver biopsies were performed, serum samples from 30 hepatitis C virus (HCV) paediatric patients (8-14 years) were analysed and compared with samples from 30 healthy subjects. All subjects were tested for the presence of serum anti-HCV antibodies. Direct biomarkers for liver fibrosis, including transforming growth factor-β1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), hyaluronic acid (HA), procollagen type III amino-terminal peptide (PIIINP) and osteopontin (OPN), were measured. The indirect biomarkers aspartate and alanine aminotransferases, albumin and bilirubin were also tested. The results revealed a significant increase in the serum marker levels in HCV-infected children compared with the healthy group, whereas albumin levels exhibited a significant decrease. Significantly higher levels of PIIINP, TIMP-1, OPN and HA were detected in HCV-infected children with moderate to severe fibrosis compared with children with mild fibrosis (p < 0.05). The diagnostic accuracy of these direct biomarkers, represented by sensitivity, specificity and positive predictive value, emphasises the utility of PIIINP, TIMP-1, OPN and HA as indicators of liver fibrosis among HCV-infected children.
Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Male , Biomarkers/blood , Hepacivirus/immunology , Hepatitis C, Chronic/complications , Liver Cirrhosis/diagnosis , Alanine Transaminase/blood , Case-Control Studies , Disease Progression , Egypt , Hepatitis C Antibodies/blood , Hepatitis C, Chronic/blood , Hyaluronic Acid/blood , Liver Cirrhosis/blood , Liver Cirrhosis/virology , Matrix Metalloproteinase 1/blood , Peptide Fragments/blood , Procollagen/blood , Sensitivity and Specificity , Tissue Inhibitor of Metalloproteinase-1/bloodABSTRACT
OBJECTIVE: To investigate the antifibrotic effects of crocetin in scleroderma fibroblasts and in sclerotic mice. METHODS: Skin fibroblasts that were isolated from three systemic scleroderma (SSc) patients and three healthy subjects were treated with crocetin (0.1, 1 or 10 μM). Cell proliferation was measured with an MTT assay. Alpha-smooth muscle actin was detected via an immunohistochemical method. Alpha 1 (I) procollagen (COL1A1), alpha 1 (III) procollagen (COL3A1), matrix metalloproteinase (MMP)-1 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 mRNA levels were measured using real-time PCR. SSc mice were established by the subcutaneous injection of bleomycin. Crocetin (50 mg/kg/d) was injected intraperitoneally for 14 days. Dermal thickness and lung fibrosis were assessed with Masson's trichrome staining. Plasma ET-1 was detected with an enzyme-linked immunosorbent assay (ELISA). Skin and lung ET-1 and COL1A1 mRNA levels were measured via real-time PCR. RESULTS: Crocetin inhibited the proliferation of SSc and normal fibroblasts, an effect that increased with crocetin concentration and incubation time. Crocetin decreased the expression of α-SMA and the levels of mRNA for COL1A1, COL3A1 and matrix metalloproteinase-1, while crocetin increased TIMP-1 mRNA levels in both SSc and normal fibroblasts. Skin and lung fibrosis was induced, and the levels of ET-1 in the plasma, skin and lungs were elevated in bleomycin-injected mice. Crocetin alleviated the thickening of the dermis and lung fibrosis; decreased COL1A1 mRNA levels in the skin and lung; and simultaneously decreased ET-1 concentrations in the plasma and ET-1 mRNA levels in the skin and lungs of the bleomycin-induced sclerotic mice, especially during the early phase (weeks 1-3). CONCLUSION: Crocetin inhibits cell proliferation, differentiation and collagen production in SSc fibroblasts. Crocetin alleviates skin and lung fibrosis in a bleomycin-induced SSc ...
Subject(s)
Animals , Female , Mice , Anticarcinogenic Agents/pharmacology , Carotenoids/pharmacology , Fibroblasts/drug effects , Scleroderma, Systemic/drug therapy , Antibiotics, Antineoplastic , Anticarcinogenic Agents/therapeutic use , Bleomycin , Carotenoids/therapeutic use , Collagen Type I/blood , Collagen Type III/blood , Enzyme-Linked Immunosorbent Assay , Endothelin-1/blood , Fibrosis , Fibroblasts/metabolism , Immunohistochemistry , Lung/drug effects , Lung/metabolism , Matrix Metalloproteinase 1/blood , Real-Time Polymerase Chain Reaction , Scleroderma, Systemic/chemically induced , Scleroderma, Systemic/pathology , Skin/drug effects , Skin/metabolism , Time Factors , Tissue Inhibitor of Metalloproteinase-1/bloodABSTRACT
FUNDAMENTO: O levosimendan é conhecido pelo seu efeito bilateral de fortalecimento contração das miofibrilas sem aumentar a demanda de oxigênio no miocárdio. A anemia é uma deterioração que causa aumento da dosagem de fármacos em pacientes com insuficiência cardíaca. OBJETIVO: No presente estudo comparamos a eficácia do tratamento com levosimendan em pacientes com insuficiência cardíaca descompensada com ou sem anemia. MÉTODOS: Foram incluídos no estudo 23 pacientes anêmicos com insuficiência cardíaca classe 3 ou 4, segundo a New York Heart Association (NYHA) e fração de ejeção abaixo de 35%. Outros 23 pacientes com o mesmo diagnóstico cardíaco, mas sem anemia, serviu como grupo controle. Ao tratamento da insuficiência cardíaca tradicional desses pacientes foi acrescido um tratamento de 24 horas de levosimendan. Amostras foram tomadas para dosar os níveis séricos do fator de necrose tumoral alfa sérico (TNF-alfa), peptídeo natriurético cerebral aminoterminal (NT-proPNB) e metaloproteinase da matriz 1 (MMP-1), antes e após a administração. RESULTADOS: Não houve diferença significativa entre os níveis séricos de TNF-alfa e MMP-1, antes e depois do tratamento (p > 0,05). Embora o nível de NT-proBNP tenha diminuído em ambos os grupos após o tratamento, não foi estatisticamente significativo (p = 0,531 e p = 0,913 para os grupos de anemia e de controle, respectivamente). Uma restauração significativa da capacidade funcional foi observada em ambos os grupos avaliados, de acordo com a NYHA (p < 0,001 e p = 0,001 para os grupos de anemia e controle, respectivamente). CONCLUSÃO: O tratamento com levosimendan apresenta efeitos semelhantes em pacientes com insuficiência cardíaca, com anemia e sem anemia. No entanto, o efeito precoce desse tratamento sobre os níveis de TNF-alfa, NT-proPNB e MMP-1 não é evidente. Ele oferece uma melhora significativa na capacidade funcional, sem a influência da anemia.
BACKGROUND: Levosimendan is known with its two-sided effects of strengthening myofibril contraction without increasing myocardial oxygen demand. Anemia is a deteriorating situation that causes increase of drug dosing in patients with heart failure. OBJECTIVES: In this study, we compared the effectiveness of levosimendan treatment in decompensated heart failure patients with or without anemia. METHODS: Twenty-three anemic patients having class 3 or 4 heart failure according to New York Heart Association (NYHA) and an ejection fraction of below 35% were included to the study. Another 23 patients with the same cardiac diagnosis but without anemia served as control group. Twenty-four hours levosimendan treatment was added to the traditional heart failure treatment of these patients. Samples were taken to measure serum tumor necrotizing factor alpha (TNF-alpha), aminoterminal pro-brain natriuretic peptide (NT-proBNP) and matrix metalloproteinase-1 (MMP-1) levels before and after the administration. RESULTS: There was no significant difference between serum TNF-alpha and MMP-1 levels before and after the treatment (p>0.05). Although NT-proBNP level decreased in both groups after the treatment this was not statistically significant (p=0.531 and p=0.913 for anemia and control groups respectively). Significant restoration of functional capacity was seen in both groups assessed according to NYHA (p<0.001 and p=0.001 for anemia and control groups respectively). CONCLUSION: Levosimendan treatment shows similar effects in heart failure patients with anemia to that of patients without anemia. However, the early effect of this treatment on TNF-alpha, NT-proBNP and MMP-1 levels is not evident. It provides significant improvement in functional capacity without influence from anemia.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Anemia/drug therapy , Heart Failure/drug therapy , Hydrazones/therapeutic use , Matrix Metalloproteinase 1/blood , Natriuretic Peptide, Brain/blood , Pyridazines/therapeutic use , Tumor Necrosis Factor-alpha/blood , Anemia/blood , Anemia/physiopathology , Chi-Square Distribution , Cardiotonic Agents/pharmacology , Cardiotonic Agents/therapeutic use , Heart Failure/blood , Heart Failure/physiopathology , Hydrazones/pharmacology , Infusions, Intravenous , Pyridazines/pharmacology , Statistics, Nonparametric , Treatment OutcomeABSTRACT
There are a group of rheumatoid arthritis [RA] patients for whom traditional markers of outcome are unhelpful. Despite of absence of these markers; still they have progressive damaging arthritis. Expression and activation of matrix metalloproteinases as MMP-3 [stromolysin-1] and MMP-1 [collagenase-1] are increased in RA patients. There are contradictory results of their role as predictors of joint damage. To study the role of MMP-3 and MMP-1 as predictors of joint damage in early RA. Seventy early RA patients of less than 12 months duration fulfilling the ACR criteria for classification of RA were enrolled in this study. They were 65 females and 5 males with mean age [30.5 +/- 3.2] years. Also 30 apparently healthy persons were studied as a control group, 15 males and 15 females with mean age of [33.5 +/- 2.8] years. All patients and control volunteers were tested for MMP-3 and MMP-1 basal serum level, using an Enzyme-Linked Immunosorbent Assay [ELISA]. The subsequent change of Larsen Radiological Score [delta Larsen] and Health Assessment Questionnaire [delta HAQ] were recorded and correlated with MMP-3 and MMP-1 over a 12 months period. The mean basal serum level of MMP-3 and MMP-1 were significantly higher in RA patients than controls [p<0.05]. MMP-3 and MMP-1 serum levels at presentation of RA patients correlated significantly with basal CRP presentation [r = 0.40, r=0.47 and p<0.05], with delta Larsen Score [r = 0.24, r = 0.31 and p<0.05], and with delta HAQ [r = 0.33, r = 0.31 and p<0.05]. The group of patients with normal CRP at presentation [= 10mg/dl] showed a significant correlation between MMP-3, MMP-1 and erosive disease during the 12 months duration [r = 0.62, r = 0.47 respectively and p<0.05]. The group of patients without erosions at presentation showed that MMP-3 and MMP-1 had stronger correlation with progression in delta Larsen Score. Serum MMP-3 and MMP-1 of early RA patients correlate significantly with disease activity and may predict functional outcome and radiological joint damage. More prolonged studies with larger numbers of patients are needed to confirm these results
Subject(s)
Humans , Male , Female , Surveys and Questionnaires , Enzyme-Linked Immunosorbent Assay , Recovery of Function , Rheumatoid Factor , C-Reactive Protein , Matrix Metalloproteinase 1/blood , Matrix Metalloproteinase 3/bloodABSTRACT
Overexpression of mucosal metalloproteinases [MMP] have been demonstrated recently in inflammatory bowel disease. Their activity can be counterbalanced by the tissue inhibitor of metalloproteinases [TIMP]. The aim of this study was to evaluate the effect of ulcerative colitis [UC] on MMP-1 and TIMP-1 plasma concentrations, as two possible biomarkers of the disease activity. MMP-1 and TIMP-1 plasma concentrations were measured with an enzyme immunoassay in 16 patients uuth endoscopically confirmed active UC and 12 healthy controls. Plasma concentrations of both MMP-1 [13.7 +/- 0.2 ng/ml] and TIMP-1 [799 +/- 140 ng/ml] were significantly elevated in UC patients In comparison to healthy controls [11.9 +/- 0.9 ng/ml. and 220 +/- 7 ng/ml respectively]. There was no correlation between TIMP-1 and MMP-1 concentrations [r=-0.02]. TIMP-1 levels revealed significant positive correlations with scored endoscopic degree of mucosal injury, disease activity index and clinical activity index values as well as C-reactive protein concentration. There was no correlation between MMP-1 and laboratory, clinical or endoscopic indices of the disease activity. These results confirm the role of both MMP-1 and TIMP-1 in the pathogenesis of ulcerative colitis. However only TIMP-1 can be useful as a biomarker of the disease activity, demonstrating association, with clinical endoscopic pictures